Found: 23
Select item for more details and to access through your institution.
Tetra-arsenic tetra-sulfide enhances NK-92MI mediated cellular immunotherapy in all-trans retinoic acid-resistant acute promyelocytic leukemia.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 6, p. 1231, doi. 10.1007/s10637-022-01313-8
- By:
- Publication type:
- Article
A phase II study of sapanisertib (TAK-228) a mTORC1/2 inhibitor in rapalog-resistant advanced pancreatic neuroendocrine tumors (PNET): ECOG-ACRIN EA2161.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 6, p. 1306, doi. 10.1007/s10637-022-01311-w
- By:
- Publication type:
- Article
Risk factors for severe immune-related adverse events after first-line pembrolizumab monotherapy or combination chemotherapy for non-small-cell lung cancer.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 6, p. 1298, doi. 10.1007/s10637-022-01310-x
- By:
- Publication type:
- Article
TRIM59 guards ER proteostasis and prevents Bortezomib-mediated colorectal cancer (CRC) cells' killing.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 6, p. 1244, doi. 10.1007/s10637-022-01306-7
- By:
- Publication type:
- Article
Relation of overall tumor burden with severe immune-related adverse events in nivolumab plus ipilimumab treatment for lung cancer.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 6, p. 1315, doi. 10.1007/s10637-022-01305-8
- By:
- Publication type:
- Article
Effects of CYP3A4/5 and ABC transporter polymorphisms on osimertinib plasma concentrations in Japanese patients with non-small cell lung cancer.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 6, p. 1254, doi. 10.1007/s10637-022-01304-9
- By:
- Publication type:
- Article
Optimal threshold of alpha-fetoprotein response in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 6, p. 1290, doi. 10.1007/s10637-022-01303-w
- By:
- Publication type:
- Article
Combination of ruxolitinib with ABT-737 exhibits synergistic effects in cells carrying concurrent JAK2<sup>V617F</sup> and ASXL1 mutations.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 6, p. 1194, doi. 10.1007/s10637-022-01297-5
- By:
- Publication type:
- Article
EGFR-TKI re-administration after osimertinib failure in T790M mutation loss cases with re-biopsy.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 6, p. 1342, doi. 10.1007/s10637-022-01301-y
- By:
- Publication type:
- Article
CD25-targeted antibody–drug conjugate camidanlumab tesirine for relapsed or refractory classical Hodgkin lymphoma.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 6, p. 1333, doi. 10.1007/s10637-022-01300-z
- By:
- Publication type:
- Article
Phase I study to evaluate of the gastric pH-dependent drug interaction between famitinib and the proton pump inhibitor omeprazole in healthy subjects.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 6, p. 1274, doi. 10.1007/s10637-022-01299-3
- By:
- Publication type:
- Article
Correction to: A novel SLC8A1/LINC01913 intergenic region-ALK fusion identified by NGS and validated by IHC and FISH in a stage IIB lung adenocarcinoma patient who remains relapse-free during the treatment of crizotinib: A case report.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Long-term response in a patient with adenocarcinoma harboring both common and uncommon EGFR mutations.
- Published in:
- 2022
- By:
- Publication type:
- Letter
Correction to: Analysis of melanoma tumor antigens and immune subtypes for the development of mRNA vaccine.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Two calix[4]pyrroles as potential therapeutics for castration-resistant prostate cancer.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 6, p. 1185, doi. 10.1007/s10637-022-01294-8
- By:
- Publication type:
- Article
Neoadjuvant immunoradiotherapy in patients with locally advanced oral cavity squamous cell carcinoma: a retrospective study.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 6, p. 1282, doi. 10.1007/s10637-022-01293-9
- By:
- Publication type:
- Article
BMP2 as a promising anticancer approach: functions and molecular mechanisms.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 6, p. 1322, doi. 10.1007/s10637-022-01298-4
- By:
- Publication type:
- Article
Ketamine promotes breast tumor growth in a mouse breast tumor model involving with high expression of miR-27b-3p and EGFR.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 6, p. 1165, doi. 10.1007/s10637-022-01291-x
- By:
- Publication type:
- Article
Analysis of melanoma tumor antigens and immune subtypes for the development of mRNA vaccine.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 6, p. 1173, doi. 10.1007/s10637-022-01290-y
- By:
- Publication type:
- Article
Carbidopa suppresses estrogen receptor-positive breast cancer via AhR-mediated proteasomal degradation of ERα.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 6, p. 1216, doi. 10.1007/s10637-022-01289-5
- By:
- Publication type:
- Article
Phase I study of lurbinectedin in combination with weekly paclitaxel with or without bevacizumab in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 6, p. 1263, doi. 10.1007/s10637-022-01281-z
- By:
- Publication type:
- Article
Comparison of dual mTORC1/2 inhibitor AZD8055 and mTORC1 inhibitor rapamycin on the metabolism of breast cancer cells using proton nuclear magnetic resonance spectroscopy metabolomics.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 6, p. 1206, doi. 10.1007/s10637-022-01268-w
- By:
- Publication type:
- Article
A novel SLC8A1/LINC01913 intergenic region-ALK fusion identified by NGS and validated by IHC and FISH in a stage IIB lung adenocarcinoma patient who remains relapse-free during the treatment of crizotinib: a case report.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 6, p. 1350, doi. 10.1007/s10637-022-01262-2
- By:
- Publication type:
- Article